Acceleration Therapeutics' AT-101 Provides Symptomatic Relief in Fibromyalgia & Chronic Fatigue Syndrome NORTH BAY VILLAGE, Fla.—June 24, 2004–Acceleration Therapeutics, a Division of Non-Invasive Monitoring Systems, Inc. (NIMS), announces the publication of a study which showed significant improvements in Role Physical, Bodily Pain, and Vitality for patients with Fibromyalgia and Chronic Fatigue Syndrome.
Patients were assessed using a health-related quality of life questionnaire. These benefits are attributed to release of nitric oxide (NO) from the inner lining of blood vessels into the circulation produced with the AT-101. The study, entitled "Say NO to Fibromyalgia and Chronic Fatigue Syndrome: An Alternative and Complementary Therapy to Aerobic Exercise," used the company's flagship product, the AT-101. The results are published in the July 2004 Medical Hypotheses. The study is authored by the company's President, Marvin A Sackner, M.D. Since NO has a documented anti-inflammatory action, such results are consistent with the notion that these diseases have chronic inflammation as their basis. Dr. Sackner and Dr. Tony Adams, Mt. Sinai Medical Center of Greater Miami, also presented two AT-101 papers at an international symposium in Rio de Janeiro, Brazil on Nitric Oxide, Cytokines and Inflammation, June 6-9, 2004. They found similar symptomatic improvements in osteoarthritis and chronic neurological diseases.
The AT-101 is a platform that moves the body repetitively head to foot at a rapid, yet comfortable pace. Acceleration Therapeutics, a division of NIMS, markets the AT-101 worldwide. The AT-101 is listed with the FDA as a Class I (exempt) passive exercise device intended as an aid to improve the circulation and joint mobility. AT-101 treatments are reimbursed by Medicare and insurance companies under CPT 97110, Therapeutic Exercises, which requires that patients have one of the following, a chronic neurological disease including fibromyalgia or chronic fatigue syndrome, rheumatological disease, soft tissue injury or bone fracture.
STUDY ABSTRACT: Say NO to fibromyalgia and chronic fatigue syndrome: an alternative and complementary therapy to aerobic exercise Marvin A. Sackner, Emerance M. Gummels and Jose A. Adams Mt. Sinai Medical Center of Greater Miami, Division of Pulmonary Disease and Critical Care Medicine and Department of Neonatology, Miami Beach, FL 33140, USA Received 28 January 2004; accepted 31 January 2004. Available online 15 April 2004.
Increased shear stress to the endothelium increases activity of endothelial nitric oxide synthase (eNOS) with subsequent release of small quantities (nMol) of nitric oxide (NO) into the circulation. It occurs during moderate aerobic exercise mostly as a result of laminar shear stress and with whole body, periodic acceleration as a result of pulsatile shear stress. The latter is administered by means of a new, non-invasive, passive exercise device. Moderate exercise has long been known to alleviate the symptoms of fibromyalgia and chronic fatigue syndrome and in the current study, whole body, periodic acceleration did as well. Since NO through action of eNOS has potent anti-inflammatory properties mainly by suppressing nuclear factor Kb activity, it is hypothesized that both diseases have chronic inflammation as their basis. Whole body periodic acceleration can be applied separately or supplementary to aerobic exercise in the treatment of fibromyalgia and chronic fatigue syndrome.
Copyright © 2004 Elsevier Ltd. All rights reserved
Acceleration Therapeutics (www.accelerationtherapeutics.com) is a leading developer of scientifically-advanced medical devices that offer effective non-invasive, drug-free treatments for people suffering from diseases, conditions and injuries that cause limited mobility or impaired circulation. The Company's first product, the AT-101, consists of a comfortable platform upon which a supine person experiences a repetitive back and forth motion from head to foot. This device can be used in a home, clinic or hospital setting. The AT-101 is registered with the FDA as a Class 1 (exempt) device. Acceleration Therapeutics is a division of Nims, Inc. (OTCBB: NIMU) a South Florida based, publicly traded company that has developed several successful products for the health care market.
Contact: Deborah Goldring, 305-861-0075 Acceleration Therapeutics firstname.lastname@example.org
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.